Cirius Therapeutics Overview
- Founded
-
2015
- Status
-
Private
- Employees
-
11
- Latest Deal Type
-
IPO
- (Cancelled)
- Latest Deal Amount
-
$86.2M
- Investors
-
5
Cirius Therapeutics General Information
Description
Developer of an insulin sensitizer drug designed for the treatment of nonalcoholic liver disease. The company's sensitizer drug is used to treat nonalcoholic steatohepatitis which is characterized by the buildup of fat and inflammation in the liver, may be accompanied by fibrosis, and can progress to life-threatening cirrhosis or liver cancer, enabling healthcare providers to treat patients of the liver and metabolic diseases and avoid recurrence of nonalcoholic steatohepatitis.
Contact Information
Website
www.ciriustx.com
Formerly Known As
Octeta Therapeutics
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Drug Discovery
Primary Office
- 12651 High Bluff Drive
- Suite 150
- San Diego, CA 92130
- United States
+1 (858) 000-0000
Cirius Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. IPO | 20-Dec-2019 | $86.2M | Cancelled | Generating Revenue | ||
| 4. Early Stage VC (Series A3) | 10-May-2019 | 00.00 | 000.00 | 00000 | Completed | Generating Revenue |
| 3. Early Stage VC (Series A3) | 23-Aug-2018 | 000 | 000.00 | 00000 | Completed | Startup |
| 2. Early Stage VC (Series A2) | 10-Apr-2017 | $40M | $56.4M | 0000 | Completed | Startup |
| 1. Early Stage VC (Series A1) | 19-May-2016 | $16.4M | $16.4M | 000.00 | Completed | Startup |
Cirius Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A3 | 0,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 0.000 |
| Series A2 | 00,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Series A1 | 17,069,451 | $0.001000 | 8% | $1 | $1 | 1x | $1 | 17.25% |
Cirius Therapeutics Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of an insulin sensitizer drug designed for the treatment of nonalcoholic liver disease. The company's sensitiz
Pharmaceuticals
San Diego, CA
11
As of 2018
000.00
00000000
00000ï
aboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate
0000000000000
Mont-Saint-Guibert, Belgium
00
As of 0000
00000
0000000000 0
00000
000000
tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitati
0000 000000000
Copenhagen, Denmark
00
As of 0000
00000
0000
0000-00-00
00000000
00000
Add Comparison
Cirius Therapeutics Competitors (58)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Cellaïon | Venture Capital-Backed | Mont-Saint-Guibert, Belgium | 00 | 00000 | 0000000000 0 | 00000 |
| 0000000 | Formerly VC-backed | Copenhagen, Denmark | 00 | 00000 | 00000000 | 00000 |
| 00000 000000000000 | Venture Capital-Backed | Paris, France | 00 | 000.00 | 0000000000 0 | 000.00 |
| 000000000(00000000 | Formerly VC-backed | New York, NY | 000 | 00000 | 000000 - 000 | 00000 |
| 00000 (0000 000000 | Venture Capital-Backed | San Diego, CA | 00 | 0000 | 000000 - 000 | 0000 |
Cirius Therapeutics Patents
Cirius Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4054568-A1 | Thiazolidinedione analogs for the treatment of nafld and metabolic diseases | Pending | 08-Nov-2019 | 0000000000 | |
| US-20220031667-A1 | Thiazolidinedione analogs for the treatment of nafld and metabolic diseases | Pending | 10-Jan-2019 | 0000000000 | |
| US-20210361629-A1 | Thiazolidinedione analogs for the treatment of nafld and metabolic diseases | Pending | 04-May-2018 | 0000000000 | |
| EP-3787618-A4 | Thiazolidinedione analogs for the treatment of nafld and metabolic diseases | Pending | 04-May-2018 | 0000000000 | 0 |
| EP-3787618-A1 | Thiazolidinedione analogs for the treatment of nafld and metabolic diseases | Pending | 04-May-2018 | A61K31/426 |
Cirius Therapeutics Executive Team (7)
Cirius Therapeutics Board Members (8)
| Name | Representing | Role | Since |
|---|---|---|---|
| Daniel Estes Ph.D | Frazier Healthcare Partners | Board Member | 000 0000 |
| David Van Andel | Cirius Therapeutics | Board Member | 000 0000 |
| Dennis Fenton Ph.D | Self | Board Member | 000 0000 |
| Michael Jandernoa | Self | Board Member | 000 0000 |
| Nilesh Kumar Ph.D | Novo Holdings | Board Member | 000 0000 |
Cirius Therapeutics Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Cirius Therapeutics Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Adams Street Partners | PE/Buyout | Minority | 000 0000 | 000000 0 | |
| Frazier Healthcare Partners | PE/Buyout | Minority | 000 0000 | 000000 0 | |
| Hopen Life Science Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Novo Holdings | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Renaissance Venture Capital | Fund of Funds | Minority | 000 0000 | 000000 0 |